Management of hepatorenal syndrome and associated outcomes: a systematic review
Open Access
- 17 April 2024
- journal article
- research article
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 11 (1) , e001319
Abstract
Background Hepatorenal syndrome (HRS), a multiorgan condition of acute kidney injury, is seen in advanced liver disease. This study aims to evaluate the current treatment for HRS. Methods The authors searched PubMed, Scopus and Google Scholar literature. After quality assessment, 31 studies were included in this review. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses methodology and the population, intervention, comparison and outcome scheme were used. We included human-controlled trials that evaluate the current treatment for HRS. Two authors independently screened articles for inclusion, extracted data and assessed the quality of included studies. Results This study investigated the studies conducted on the effects of different treatments on follow-up of HRS patients. We gathered 440 articles, so 31 articles remained in our study. Of which 24 articles were conducted on terlipressin versus placebo or other treatments (midodrine/octreotide, norepinephrine, etc) that showed the higher rate of HRS reversal was detected for terlipressin in 17 studies (10 of them were significant), 2 studies achieved an insignificant lower rate of the model for end-stage liver disease score for terlipressin, 15 studies showed a decreased mortality rate in the terlipressin group (4 of them were significant). Conclusion This review showed that terlipressin has a significantly higher reversal rate of HRS than the other treatments. Even the results showed that terlipressin is more efficient than midodrine/octreotide and norepinephrine as a previous medication, in reverse HRS, increasing patient survival.Keywords
This publication has 46 references indexed in Scilit:
- Terlipressin in combination with albumin as a therapy for hepatorenal syndrome in patients aged 65 years or olderAnnals of Hepatology, 2023
- Combination of terlipressin and noradrenaline versus terlipressin in hepatorenal syndrome with early non-response to terlipressin infusion: A randomized trialIndian Journal of Gastroenterology, 2023
- Effect of the response to preoperative treatment for hepatorenal syndrome on the outcome of recipients of living‐donor liver transplantationJournal of Hepato-Biliary-Pancreatic Sciences, 2022
- Renal Failure in Cirrhosis2022
- Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver FailureHepatology, 2019
- Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled studyIndian Journal of Gastroenterology, 2018
- Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled studyHepatology, 2016
- Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trialHepatology, 2015
- Terlipressin and Albumin in Patients with Cirrhosis and Type I Hepatorenal SyndromeDigestive Diseases and Sciences, 2007
- Reversal of Type 1 Hepatorenal Syndrome With the Administration of Midodrine and OctreotideHepatology, 1999